Pediatrix Q2 2026: Adjusted EPS $0.63, revenue $488M, reaffirms FY EBITDA $280-300M

Pediatrix Medical Group, Inc.

Net revenue $487.8M, up 4.0% YoY; net income $39.8M ($0.49 diluted EPS) vs $39.3M ($0.46) YoY.
Adjusted EPS $0.63 vs $0.53 YoY; Adjusted EBITDA $76.4M vs $73.2M YoY.
Same-unit revenue up 1.9% (reimbursement +4.0%, volume -2.1%); NICU days down 3.2%.
Reaffirmed FY 2026 Adjusted EBITDA guidance of $280M-$300M.
Used $42.7M for share repurchases in Q2; total debt $584M, cash $288.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.